MetaCap

BioVie Inc. Class A (BIVI)

NASDAQ: BIVIHealth CareBiotechnology: Pharmaceutical PreparationsUSD

0.80-0.1098 (-12.07%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

BIVI stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$2.85
52-week range
0.7515 – 3.79
Day range
0.7515 – 0.9104
Volume / Avg
399.58K / 568.61K
Beta
—
Next earnings
Feb 5, 2027

52-week range

$0.7515$3.79

BIVI stock today

On Nov 20, BIVI ended the session at $0.80, shedding $0.1098 (12.07%), versus the S&P 500's 3.70% decline. At this level, BIVI sits near the bottom of its 52-week range of $0.7515 to $3.79: 78.9% below the high, set on Aug 12, 2026 and 6.5% above the low. BIVI is down 31.0% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 38.2%.

BioVie has posted a net loss over the last twelve months (EPS of -$2.85), so its P/E ratio is not meaningful. BioVie's next earnings report is expected on Feb 5, 2027.

Summary generated from market data by MetaCap's automated system. Methodology

About BioVie

Company profile

BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States. The company develops BIV201, that is in phase 3 for the treatment of life-threatening complications of liver cirrhosis and ascites due to hepatitis, nonalcoholic steatohepatitis, and alcoholism. It also develops Bezisterim, an investigational, novel, orally administered small molecule that is In Phase 3 clinical trial for the treatment of patients with mild to moderate Alzheimer's disease; and in Phase 2b clinical trial to treat Parkinson's disease, as well as for the long COVID program.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Cuong Viet Do M.B.A.
Headquarters
Carson City, NV
Employees
13

Financial highlights

Full financials

BioVie reported a net loss of $22.1 million, compared with a loss of $17.5 million a year earlier. Diluted earnings per share came in at -$3.05.

BioVie annual revenue, net income and EPS
Fiscal yearFY 2026FY 2025FY 2024FY 2023FY 2022
Revenue—————
Growth—————
Net income$-22.07M$-17.54M$-32.12M$-50.26M$-26.08M
EPS (diluted)$-3.05$-12.12$-73.05$-15.47$-1.06

Analyst forecast

Forecast

Consensus (2 analysts)

none

Avg. price target

$5.26+557.50%

  • Strong buy 0
  • Buy 2
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $5.00High $5.51

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Next report
Feb 5, 2027
Last reported (Sep/2026)
Nov 9, 2026
EPS actual vs est.
$-0.68 vs —

BIVI news

All BIVI news

BioVie peers

Health Care sector
BIVI peer companies
CompanyPrice% ChgMarket capCompare
OPTHOptimi Health Corp.1.51-13.71%$8.65Mvs BIVI
LEXXLexaria Bioscience Corp.4.03-10.24%$8.49Mvs BIVI
CALCCalciMedica Inc.1.26+7.69%$8.69Mvs BIVI
HINDVyome Holdings Inc.1.20-17.24%$8.42Mvs BIVI
QNTMQuantum Biopharma Ltd. Class B Subordinate Voting Shares1.29-9.15%$8.29Mvs BIVI
MBRXMoleculin Biotech Inc.7.74-2.40%$8.22Mvs BIVI
PTNPalatin Technologies Inc.4.58-7.10%$8.16Mvs BIVI
GDTCCytoMed Therapeutics Limited0.755-2.33%$9.01Mvs BIVI

Indexes, lists and sector

BioVie stock FAQ

What is BioVie's stock price today?

BIVI last traded at $0.80 as of Nov 20, 4:00 PM EST, down 12.07% on the day. Prices are delayed at least 15 minutes.

Does BioVie pay a dividend?

No. BioVie does not currently pay a regular cash dividend.

When is BioVie's next earnings date?

BioVie is expected to report earnings on Friday, February 5, 2027.

Who is BioVie's CEO?

Mr. Cuong Viet Do M.B.A. is the chief executive officer of BioVie Inc. Class A, which has about 13 employees.

Has BIVI ever split its stock?

Yes. The most recent BIVI stock split was a 1-for-10 split on Jul 7, 2025, one of 2 splits on record.

What is the BIVI 52-week high?

The 52-week high for BIVI is $3.79 and the 52-week low is $0.7515. The stock is currently 78.9% below its high.

Compare BIVI